激活ROCK/MYLK通路会影响与眼睛高血压相关的带网的复杂分子和形态变化
Chia-Chen Hsu1, Fang-Pai Lin2, Hao-Chen Tseng2
1Department of Ophthalmology, Tri-Service General Hospital, National Defense Medical Center, Taipei, Taiwan.
Investigative ophthalmology & visual science
|August 8, 2024
概括
罗相关蛋白激酶和髓轻链激酶 (ROCK/MYLK) 途径在初级开角玻璃眼 (POAG) 中至关重要. 抑制这种途径降低了子模型中的眼内压力,并揭示了POAG患者的关键基因差异.
科学领域:
- 眼科医生 眼科 眼科
- 分子生物学分子生物学
- 药理学 药理学是指药理学的学科.
背景情况:
- 主要开角玻璃眼 (POAG) 病理生理学涉及Rho关联蛋白激酶和肌轻链激酶 (ROCK/MYLK) 途径.
- 带状网 (TM) 是POAG中受影响的关键组织,影响眼内压力 (IOP).
研究的目的:
- 通过眼睛高血压 (OHT) 子模型和人类临床数据,研究ROCK/MYLK途径在POAG中的作用.
- 在POAG管理的TM中确定新的治疗点.
主要方法:
- 在子中,通过微珠注射诱导眼睛高血压,然后用双重ROCK/MYLK抑制剂 (ITRI-E-(S) -4046) 治疗.
- 在子模型中测量了眼内压力 (IOP) 和TM空隙空间.
- 整个转录基因组测序是从早期和晚期POAG患者的TM组织上进行的,这些患者接受了轨道切除术.
主要成果:
- 在OHT子中,用ITRI-E-(S) -4046治疗显著降低了IOP (P <0.05) 和增加了TM空隙空间 (P <0.0001).
- 在POAG患者中确定了103个与Rho家族GTPase通路相关的差异表达基因 (DEGs) (P = 1.25E-10).
- 在早期和晚期POAG之间观察到显著的基因表达差异.
结论:
- ROCK/MYLK通路在OHT相关的青光瘤和不同类型的POAG发病中具有关键作用.
- 这些发现提供了对POAG.POAG的TM相关分子机制的见解.
- 针对ROCK/MYLK途径为POAG提供了一个有前途的治疗策略.
相关概念视频
Open Angle Glaucoma: Treatment
413
In open-angle glaucoma, the iridocorneal angle remains open, but the trabecular meshwork becomes stiff, slowing down the outflow of aqueous humor. This causes a buildup of aqueous humor in the anterior chamber, leading to a sudden increase in intraocular pressure. The treatment for open-angle glaucoma focuses on reducing the elevated intraocular pressure by either decreasing the secretion of aqueous humor or increasing its outflow.
Drugs such as carbonic anhydrase inhibitors, α2- and...
Drugs such as carbonic anhydrase inhibitors, α2- and...
413
Glaucoma: Overview
530
Glaucoma is an eye condition characterized by increased intraocular pressure that damages the retina and optic nerve, leading to irreversible blindness if left untreated. The human eye has various components, including the cornea, iris, pupil, lens, and optic nerve. Aqueous humor is secreted by the epithelium of the ciliary body in the posterior chamber and flows through the trabecular meshwork and canal of Schlemm, maintaining normal intraocular pressure. The trabecular meshwork and the canal...
530
PI3K/mTOR/AKT Signaling Pathway
3.5K
The mammalian target of rapamycin (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1 (mTORC1) and mTOR complex 2 (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast, mTORC2 consists of a...
3.5K
mTOR Signaling and Cancer Progression
3.8K
The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
The mTOR pathway or the...
3.8K
Angle Closure Glaucoma: Treatment
459
Angle-closure glaucoma, or closed-angle glaucoma, is an eye condition where the iris bulges out and blocks the iridocorneal angle, resulting in a buildup of aqueous humor and increased intraocular pressure. Immediate medical attention is necessary due to the sudden onset of symptoms. The treatment for angle-closure glaucoma includes short-term and long-term approaches. Short-term treatment involves using eye drops like pilocarpine to lower intraocular pressure by increasing aqueous humor...
459


